Glucose-6-phosphate dehydrogenase: a therapeutic target for ovarian cancer.
Expert Opin Ther Targets
; 27(8): 733-743, 2023.
Article
en En
| MEDLINE
| ID: mdl-37571851
ABSTRACT
INTRODUCTION:
Ovarian cancer (OC) is a gynecological tumor disease, which is usually diagnosed at an advanced stage and has a poor prognosis. It has been established that the glucose metabolism rate of cancer cells is significantly higher than that of normal cells, and the pentose phosphate pathway (PPP) is an important branch pathway for glucose metabolism. Glucose-6-phosphate dehydrogenase (G6PD) is the key rate-limiting enzyme in the PPP, which plays an important role in the initiation and development of cancer (such as OC), and has been considered as a promisinganti-cancer target. AREAS COVERED In this review, based on the structure and biological function of G6PD, recent research on the roles of G6PD in the progression, metastasis, and chemoresistance of OC are summarized and accompanied by proposed molecular mechanisms, which may provide a systematic understanding of targeting G6PD for the treatment of patients with OC. EXPERT OPINION Accumulating evidence demonstrates that G6PD is a promising target of cancer. The development of G6PD inhibitors for cancer treatment merits broad application prospects.Palabras clave
Texto completo:
1
Colección:
01-internacional
Asunto principal:
Neoplasias Ováricas
/
Glucosafosfato Deshidrogenasa
Límite:
Female
/
Humans
Idioma:
En
Revista:
Expert Opin Ther Targets
Asunto de la revista:
TERAPEUTICA
Año:
2023
Tipo del documento:
Article
País de afiliación:
China